These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 27770973)

  • 1. The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC.
    Aguiar PN; Perry LA; Penny-Dimri J; Babiker H; Tadokoro H; de Mello RA; Lopes GL
    Ann Oncol; 2017 Sep; 28(9):2256-2263. PubMed ID: 28633409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
    Shih YT; Cortes JE; Kantarjian HM
    Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Financial toxicity and implications for cancer care in the era of molecular and immune therapies.
    Tran G; Zafar SY
    Ann Transl Med; 2018 May; 6(9):166. PubMed ID: 29911114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
    Langer CJ
    Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?
    Cheng M; Durm G; Hanna N; Einhorn LH; Kong FS
    Future Oncol; 2017 Dec; 13(28):2503-2505. PubMed ID: 29168656
    [No Abstract]   [Full Text] [Related]  

  • 6. The "value" of immune-checkpoint inhibitors for advanced lung cancer.
    Inoue A
    Respir Investig; 2017 Jul; 55(4):253-254. PubMed ID: 28705302
    [No Abstract]   [Full Text] [Related]  

  • 7. Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction.
    Socinski MA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S1-2. PubMed ID: 26477469
    [No Abstract]   [Full Text] [Related]  

  • 8. Checkpoint Inhibitors in Lung Cancer Are Not Immune from Cost-Effectiveness Analysis.
    Kelly RJ; Smith TJ
    J Thorac Oncol; 2016 Nov; 11(11):1814-1816. PubMed ID: 27770973
    [No Abstract]   [Full Text] [Related]  

  • 9. The next frontier in non-small cell lung cancer: synergizing radiation therapy and immune checkpoint blockade.
    Voong KR; Naidoo J; Ettinger DS
    Clin Adv Hematol Oncol; 2017 Aug; 15(8):615-625. PubMed ID: 28949949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of immunotherapy in lung cancer: Preliminary results of new vaccines and immune checkpoint inhibitors.
    John T
    Asia Pac J Clin Oncol; 2015 Apr; 11 Suppl 1():2-8. PubMed ID: 25913639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors in lung cancer: current status and future directions.
    Fan Y; Mao W
    Chin Clin Oncol; 2017 Apr; 6(2):17. PubMed ID: 28482670
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.